Upcoming event

Keynote-057 study: interim analysis

October 2019

Phase 2 TROPHY-U-01 open-label study of patients receiving sacituzumab-govitecan with metastatic urothelial cancer after failure of platinum-based regimens or immunotherapy by Scott Tagawa

Ocotber 2019

Previous